Autonomix Announces Reverse Stock Split

Rhea-AI Summary

Autonomix (NASDAQ: AMIX) approved a 1-for-21 reverse stock split of its common stock, effective 12:01 a.m. ET on June 24, 2026. Shares will continue trading on Nasdaq under AMIX with new CUSIP 05330T304.

The split reduces outstanding shares from about 11.4 million to about 543,000, with par value unchanged at $0.001. Fractional shares will not be issued; holders will receive cash instead. Authorized shares remain at 500 million, and equity plan reserves will be proportionately reduced.

AI-generated analysis. Not financial advice.

Positive

• 1-for-21 reverse stock split effective June 24, 2026
• Outstanding shares reduced from ~11.4 million to ~543,000
• No change to $0.001 par value per share
• Equity compensation plan share reserve reduced proportionately

Negative

• None.

Key Figures

Reverse split ratio: 1-for-21 Shares outstanding pre-split: approximately 11.4 million shares Shares outstanding post-split: approximately 543,000 shares +5 more

8 metrics

Reverse split ratio 1-for-21 Common stock reverse split effective June 24, 2026

Shares outstanding pre-split approximately 11.4 million shares Common stock before 1-for-21 reverse split

Shares outstanding post-split approximately 543,000 shares Common stock after 1-for-21 reverse split

Authorized shares 500 million shares Authorized common stock remains unchanged after reverse split

Accumulated deficit $67.1 million As of March 31, 2026 (10-K)

Operating cash flow -$12.3 million Negative operating cash flow, fiscal 2026 (10-K)

Net loss $14.0 million Nine months ended December 31, 2025 (10-Q)

Additional financing need $30–$36 million Estimated funding required to reach first commercialization (10-Q)

Historical Context

5 past events · Latest: Jun 10 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jun 10	Management update	Positive	-6.5%	CEO segment highlighting growing scientific and clinical recognition of platform.
Jun 04	Clinical data	Positive	+3.6%	Clinical data discussion on visceral cancer pain and platform potential.
May 19	Patent granted	Positive	-10.0%	New U.S. patent covering transvascular monitoring and treatment systems.
May 18	Abstracts accepted	Positive	-3.0%	EuroPCR 2026 abstract acceptances on pancreatic cancer pain mitigation data.
Apr 29	Abstract acceptance	Positive	-6.7%	Digestive Disease Week 2026 abstract on long-term pancreatic cancer pain outcomes.

Pattern Detected

Recent history shows frequent negative price reactions even to seemingly positive operational updates.

Regulatory & Risk Context

Active S-3 Shelf · $7.7 million · Short Interest: 11.06%

Shelf Active

Short Interest

11.06% of float

0% 15% 30%+

moderate as of 2026-05-29 Days to cover: 1

Short interest is at a moderately elevated level, suggesting scope for increased volatility but not an extreme short-squeeze setup based on current positioning.

Active S-3 Shelf Registration 2025-11-26

$7.7 million registered capacity

An effective S-3 shelf for resale of warrant shares allows a selling stockholder to resell shares while the company could receive cash proceeds only if common warrants are exercised for cash.

Market Pulse Summary

This announcement centers on a 1-for-21 reverse split reducing outstanding shares to roughly 543,000...

Analysis

This announcement centers on a 1-for-21 reverse split reducing outstanding shares to roughly 543,000 while keeping 500 million authorized. A resale shelf and moderate short positioning add overhang; investors may watch how post-split liquidity develops.

Key Terms

reverse stock split, cusip, par value, equity compensation plan

4 terms

reverse stock split financial

"to effect a 1-for-21 reverse stock split of its common stock."

A reverse stock split is when a company reduces the number of its shares outstanding, making each share more valuable. For example, if you own 100 shares worth $1 each, a 1-for-10 reverse split would turn your 100 shares into 10 shares worth $10 each. Companies often do this to boost their stock price and appear more stable to investors.

cusip financial

"under the existing ticker symbol “AMIX” but with a new CUSIP number 05330T304."

A CUSIP is a nine-character alphanumeric code that uniquely identifies a U.S. or Canadian financial security—such as a stock, bond, or fund share—like a Social Security number for an investment. It matters to investors because brokers, exchanges and record-keepers use the CUSIP to match trades, track ownership, settle transactions and pull accurate records, reducing errors and ensuring money and securities go to the right place.

par value financial

"with no change in the nominal par value per share of $0.001."

Par value is the fixed amount printed on a bond or stock that represents its original value when issued. It’s like the face value of a coin or bill—what the issuer promises to pay back or the starting price of a stock—though it often doesn’t change with market prices. It matters because it helps determine certain financial details, like how much the company will pay back at maturity.

equity compensation plan financial

"the number of shares reserved for issuance under the Company’s equity compensation plan"

A plan by which a company gives employees, directors or contractors ownership or the right to buy ownership in the company through stock, options or similar awards — think of promising slices of the company pie as part of someone's pay. It matters to investors because these awards can change the number of shares outstanding, affect reported profits and influence management’s decisions; large or generous plans can dilute existing holders and alter incentives over time.

AI-generated analysis. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

THE WOODLANDS, TX, June 18, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that it filed an amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a 1-for-21 reverse stock split of its common stock. The reverse stock split will take effect at 12:01 am (Eastern Time) on June 24, 2026, and the Company’s common stock will open for trading on The Nasdaq Capital Market on June 24, 2026 on a post-split basis, under the existing ticker symbol “AMIX” but with a new CUSIP number 05330T304.

As a result of the reverse stock split, every 21 shares of the Company’s common stock issued and outstanding prior to the opening of trading on June 24, 2026 will be consolidated into one issued and outstanding share, with no change in the nominal par value per share of $0.001. No fractional shares will be issued, if, as a result of the reverse stock split, a stockholder would become entitled to a fractional share because the number of shares of common stock they hold before the reverse stock split is not evenly divisible by the split ratio. Instead, the stockholder will be entitled to receive a cash payment in lieu of a fractional share.

As a result of the reverse stock split, the number of shares of common stock outstanding will be reduced from approximately 11.4 million shares to approximately 543,000 shares, and the number of authorized shares of common stock will remain at 500 million shares. In addition, the number of shares reserved for issuance under the Company’s equity compensation plan immediately prior to the reverse stock split will be reduced proportionately.

About Autonomix Medical, Inc.

Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.

We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.

For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.

Forward Looking Statements

Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the timing and completion of the reverse split. Such forward-looking statements can be identified by the use of words such as “should,” “might,” “may,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “forecasts,” “expects,” “plans,” and “proposes.”

Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on May 27, 2026. Forward-looking statements speak only as of the date of the document in which they are contained and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.

Investor and Media Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
autonomix@jtcir.com

FAQ

What is the reverse stock split ratio for Autonomix (NASDAQ: AMIX) in June 2026?

Autonomix is implementing a 1-for-21 reverse stock split of its common stock. According to Autonomix, every 21 pre-split shares will be consolidated into one post-split share, with no change to the $0.001 par value per share.

When does the Autonomix (AMIX) reverse stock split take effect and start trading?

The Autonomix reverse stock split takes effect at 12:01 a.m. ET on June 24, 2026. According to Autonomix, the stock will begin trading on a post-split basis on Nasdaq that same day under the existing ticker symbol AMIX.

How will Autonomix’s (AMIX) shares outstanding change after the June 2026 reverse split?

Autonomix’s outstanding common shares will decrease from about 11.4 million to about 543,000. According to Autonomix, this reduction reflects the 1-for-21 consolidation, while the total authorized common shares will remain at 500 million after the split.

What happens to fractional shares in the Autonomix (AMIX) 1-for-21 reverse split?

Fractional shares will not be issued in the Autonomix reverse split. According to Autonomix, shareholders whose holdings are not evenly divisible by 21 will receive a cash payment in lieu of any resulting fractional share of common stock.

Will the Autonomix (AMIX) ticker or CUSIP change after the June 24, 2026 reverse split?

The Autonomix ticker symbol AMIX will stay the same after the reverse split. According to Autonomix, only the CUSIP number will change, becoming 05330T304 when trading begins on a post-split basis.

How does the Autonomix (AMIX) reverse split affect its equity compensation plan shares?

Shares reserved under Autonomix’s equity compensation plan will be reduced proportionately to the 1-for-21 ratio. According to Autonomix, this adjustment aligns plan share availability with the lower post-split share count while keeping authorized common shares at 500 million.